There are now even shorter treatments for hepatitis C.
In less than a month, the FDA approved a second medication for hepatitis C virus (HCV) infection. The newer entry into the treatment arena is the first drug capable of suppressing viral load to undetectable levels in only 8 weeks.
Marketed as Mavyret, the recently approved medication is a combination of glecaprevir and pibrentasvir. Clinical trials involving about 2300 adults with any of the 6 HCV genotypes showed that 92% or more who received the combination for 8, 12, or 16 weeks had no detectable virus in their blood 12 weeks after treatment ended, suggesting their infections were cured.
|Read Full Article: The 8-Week Cure for Hepatitis C | Infectious Diseases | JAMA | The JAMA Network|